Drug name
Last update: Sep 2026VH-5356136 (VH5356136)
Developer(s)
Drug information
Not provided
VH5356136 (prodrug of VH-184 (VH4524184), and releases it as a metabolite)
Not applicable (investigational; no brand name assigned)
Small molecule
Integrase strand transfer inhibitor (INSTI); precursor of the third-generation INSTI VH4524184 (VH-184)
VH5356136 is an investigational compound from ViiV Healthcare related to VH4524184 (VH-184), ViiV's 3rd generation INSTI. The trial entry NCT07822477 describes VH4524184 as its parent compound and measures VH4524184 as a metabolite of VH5356136, which is consistent with a prodrug of VH-184; ViiV has not publicly confirmed the chemistry, mechanism or intended dosing interval, and the moldecule is not apparent in the company pipeline yet. VH-184 itself has shown an enhanced in vitro resistance profile versus second-generation INSTIs, and its long-acting injectable formulations (SC/IM) were reported at CROI 2026 to support monthly/two-monthly (formulation A) or six-monthly (formulation B) dosing. VH5356136 is entering a first-time-in-human, single-dose phase 1 study of two formulations in adults without HIV (planned start November 2026).
Not approved. Phase 1 (not yet recruiting; planned start 6 November 2026).
investigational
Therapeutic area(s)
- HIV
- Pre-Exposure Prophylaxis (PrEP)
- Treatment
Administration route
Route of administration is being determined in the clinical program
Associated long-acting platforms
Unknown
Use of drug
- To be determined
- Other/Variable/Unknown : To be determined based on clinical development
to be determined
Dosage
to be determined
to be determined
to be determined
Not provided
Not provided
Related entries
Main compound
VH-5356136 (VH5356136)
Related compounds
VH-184 (VH-4524184)
Additional information
Developer(s)
ViiV Healthcare
Drug structure
Scale-up and manufacturing prospects
Manufacturing information is not currently available for this compound.
Not provided
Not provided
Not provided
Excipients & delivery device(s)
Not provided
Not provided
Not provided
Not provided
Safety, Efficacy and Evidence Summary
Not provided
Not provided
Not provided
Not provided
There are either no relevant patents or these were not yet submitted to LAPaL